Elsevier

Journal of Infection

Volume 81, Issue 4, October 2020, Pages 647-679
Journal of Infection

Letter to the Editor
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

https://doi.org/10.1016/j.jinf.2020.06.052Get rights and content

Highlights

  • Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry.

  • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate.

  • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia.

  • Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab.

  • Baricitinib used for 2 weeks was not associated with serious adverse events.

Keywords

COVID-19
Baricitinib
JAK1/2
Pneumonia
Retrospective study
SARS-Co-V2

Cited by (0)

Collaborators. Vieri Vannucchi MD, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence; Monica Todoerti, MD, Rheumatology  Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Massimiliano Parodi, MD, Rheumatology  Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Paola Rossi, MD, Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Piero Davio, MD, Internal Medicine Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Pinuccia Omodeo, MD, Pulmonary Diseases Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Guido Chichino, MD, Infectious Diseases Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Ernesto Cristiano Lauritano, MD, Emergency Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Antonio Maconi, IRFI Infrastructure Research, Education, Innovation, AO SS. Antonio e Biagio e C. Arrigo – Alessandria; Anna Maria Di Carlo, Consultant, Division of Internal Medicine, Azienda Ospedaliera Ospedali RiunitiMarche Nord, Fano; Rita Girolimetti, Consultant, Division of Internal Medicine, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro; Chiara Pelosi, Consultant, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Annamaria Bellizzi, Consultant, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Luca Franco, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Italy

ClinicalTrials.gov Identifier: NCT04358614.

View Abstract